Icahn School of Medicine at Mount Sinai
New York, 10029, United States
Location status: Recruiting
Location contact
Chinara Tate
CONTACT
Chinara Tate
PRINCIPAL_INVESTIGATOR
Tom Hildebrandt
CONTACT
NCT Number: NCT05197309
This is an interventional study that will test the safety, tolerability, and efficacy of the Metabolic Diet, which was designed as a treatment for women with anorexia nervosa to remain weight-stable after they have been restored from low weight. Participants will be adult women with anorexia nervosa who have been recently restored to normal weight and adult women with no history of eating disorders. After enrollment, participants will start meeting weekly with a registered dietitian to implement the Metabolic Diet in their daily lives, and will receive medical monitoring for adherence, side effects, changes in metabolic or psychological parameters, and weight stability.
Interested in participating?
Request Info18 year–40 year
Female
Interventional
Not applicable
New York, 10029, United States
Location status: Recruiting
Chinara Tate
CONTACT
Chinara Tate
PRINCIPAL_INVESTIGATOR
Tom Hildebrandt
CONTACT
The study plan to enroll a total of 20 subjects from the broader New York City area into an 8-week eating behavioral program. Of the 20, 10 will be weight-restored patients with anorexia nervosa (WR-AN) and the other 10 will be age-, sex-, and body mass index (i.e. weight) matched healthy controls (HC).
The primary study intervention is an eating behavioral program called, Metabolic Diet, which is aimed to change the proportion of macronutrients in their meals to incorporate higher fat content and lower the carbohydrate content to limit fluctuations in circulating blood glucose levels throughout the day, which may contribute to a relapse in anorexia nervosa. Participants will be guided to start the Metabolic Diet following the first 2 individual study visits, and the duration of the primary intervention is for 8 weeks. As part of the intervention, each subject will keep a food log and measure the urinary ketones at home, which they will discuss with the study providers during weekly visits. Each subject will meet individually with the Study Dietician and with the Study Physician on a weekly basis. At these visits, food logs and ketone logs will be reviewed so that subjects' adherence to the Metabolic Diet can be assessed and facilitated.
Surveys and lab work are completed during screening, week 4 and week 8.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
*Subjects are to be free of any medications that could affect metabolism, as discussed with study physician, for 2 weeks prior to primary study visit for glucose function testing.
Metabolic Diet includes increasing the amount of foods high in fat and decreasing the amount of foods that may cause increased flux in blood glucose levels. Food logs and ketone logs will be reviewed weekly during the 8 weeks of the intervention.
Time frame: 10 weeks
Safety of intervention will be measured by # of adverse events reported over 10 weeks. Adverse events will be documented during each of the 8 weekly clinician visits.
Time frame: 10 weeks
Tolerability of intervention will be measured using percent completion of food over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.
Time frame: Baseline to 10 weeks
Tolerability of intervention will be measured using percent completion of ketone logs over 10 weeks. Logs are collected during each of the 8 weekly clinician visits.
Time frame: Baseline and 10 weeks
Weight will be calculated using the baseline weight and weight at the 10 week assessment. Weight will be during each of the 8 weekly clinician visits.
Time frame: Baseline and 10 weeks
Changes in Dietary Behavior using the Eating Disorder Examination Questionnaire (EDE-Q). Dietary restraint, eating, shape, and weight concerns are measured with the EDE-Q at multiple time points. Subscales for dietary restraint, eating, shape, and weight (subscales range from 0-6) concerns are summed and then divided by the total number of subscales (4) to create a global score (total scale 0 to 6). Higher scores on the global scale and subscales indicate more problematic eating behaviors and attitudes. Changes in the EDE-Q global score will be calculated using the baseline and 10 week assessments.
Time frame: Baseline and 10 weeks
The intensity and physical symptoms of anxiety are measures with the BAI at baseline and 10 weeks. Scores may range from 0 to 63. Higher scores indicate more intense anxiety symptoms. Changes in the BAI score will be calculated using the baselines and 10 week assessments.
Time frame: Baseline and 10 weeks
Depression is measured with the QIDS at baseline and 10 weeks. Scores may range from 0 to 27. Higher scores indicate a higher severity of depression. Changes in the QIDS score will be calculated using the baselines and 10 week assessments.
Time frame: Baseline and 10 weeks
Psychosocial functioning from eating disorders is measured using the CIA. Scores range from 0 to 48. Higher scores indicate more impairment associated with an eating disorder.
Time frame: Baseline and 10 weeks
Quality of life is measured using the QLESQ. Scores range from 14 to 70 and higher scores indicate a quality.
Time frame: Baseline and 10 weeks
The laboratory test to measure the amount of carbon dioxide in the liquid part of the blood, called the serum.
In the body, most of the CO2 is in the form of a substance called bicarbonate (HCO3-). Therefore, the CO2 blood test is really a measure of the blood bicarbonate level.
Time frame: Baseline and 10 weeks
Potassium test measures the amount of potassium in the fluid portion (serum) of the blood. Potassium (K+) helps nerves and muscles communicate. It also helps move nutrients into cells and waste products out of cells.
Time frame: Baseline and 10 weeks
The sodium blood test measures the concentration of sodium in the blood.
Time frame: Baseline and 10 weeks
Chloride is a type of electrolyte. It works with other electrolytes such as potassium, sodium, and carbon dioxide (CO2). These substances help keep the proper balance of body fluids and maintain the body's acid-base balance.
Time frame: Baseline and 10 weeks
The calcium blood test measures the level of calcium in the blood. All cells need calcium in order to work. Calcium helps build strong bones and teeth. It is important for heart function, and helps with muscle contraction, nerve signaling, and blood clotting.
Time frame: Baseline and 10 weeks
The creatinine blood test measures the level of creatinine in the blood. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply energy mainly to muscles.
This test is done to see how well your kidneys work. Creatinine is removed from the body entirely by the kidneys. If kidney function is not normal, the creatinine level in your blood will increase. This is because less creatinine is excreted through your urine.
Time frame: Baseline and 10 weeks
Urea nitrogen is what forms when protein breaks down. The BUN test measures the amount of urea nitrogen in the blood and is often done to check kidney function.
Time frame: Baseline and 10 weeks
WBC count is a blood test to measure the number of white blood cells (WBCs) in the blood.
WBCs are also called leukocytes. They help fight infections.
Time frame: Baseline and 10 weeks
An RBC count is a blood test that measures amount of red blood cells (RBCs).
RBCs contain hemoglobin, which carries oxygen. How much oxygen the body tissues get depends on amount of RBCs and how well they work.
Time frame: Baseline and 10 weeks
Hemoglobin is a protein in red blood cells that carries oxygen. The hemoglobin test measures how much hemoglobin is in your blood.
Time frame: Baseline and 10 weeks
Hematocrit is a blood test that measures how much of a person's blood is made up of red blood cells. This measurement depends on the number of and size of the red blood cells.
Time frame: Baseline and 10 weeks
A platelet count is a lab test to measure how many platelets is in the blood. Platelets are parts of the blood that help the blood clot. They are smaller than red or white blood cells.
Time frame: Baseline and 10 weeks
A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well a person is controlling your blood sugar to help prevent complications from diabetes.
Time frame: Baseline and 10 weeks
A blood sugar test measures the amount of a sugar called glucose in the blood. Glucose is a major source of energy for most cells of the body, including brain cells. Glucose is a building block for carbohydrates. Carbohydrates are quickly turned into glucose in the body. This can raise the blood glucose level.
Hormones made in the body help control blood glucose level.
Time frame: Baseline and 10 weeks
Cholesterol is a fat (also called a lipid) that your body needs to work properly. Too much bad cholesterol can increase your chance of getting heart disease, stroke, and other problems.
Time frame: Baseline and 10 weeks
HDL is one of the three main types of lipoproteins and part of the lipid panel.
Time frame: Baseline and 10 weeks
LDL is one of the three main types of lipoproteins and part of the lipid panel.
Time frame: Baseline and 10 weeks
The triglyceride level is a blood test to measure the amount of triglycerides in the blood. Triglycerides are a type of fat.
Time frame: Baseline and 10 weeks
The aspartate aminotransferase (AST) blood test measures the level of the enzyme AST in the blood. AST is an enzyme found in high levels in the liver, heart, and muscles. It is also found in lesser amounts in other tissues. An enzyme is a protein that causes a specific chemical change in the body.
Time frame: Baseline and 10 weeks
The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body.
Time frame: Baseline and 10 weeks
Albumin is a protein made by the liver. A serum albumin test measures the amount of this protein in the clear liquid portion of the blood.
Contact information is provided by the study sponsor or research team.
Chinara Tate
CONTACT
Tom Hildebrandt
CONTACT
Icahn School of Medicine at Mount Sinai
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07600671
Anorexia Nervosa, Binge Eating Disorder
Lebanon, New Hampshire, United States
View Trial DetailsNCT05918835
Anorexia Nervosa, Feeding and Eating Disorders
New York, United States
View Trial DetailsNCT07580209
Anorexia Nervosa, Feeding and Eating Disorders
Zurich, Switzerland
View Trial DetailsNCT06198023
Anorexia Nervosa, Anxiety Disorders
Dallas, Texas, United States
View Trial Details